Advances in and the potential of vaccines for respiratory syncytial virus (Q38130514)

29 August 2017

Advances in and the potential of vaccines for respiratory syncytial virus (English)

1 reference

29 August 2017

Patricia A Jorquera

1

1 reference

PubMed ID

23964629

29 August 2017

Katie E Oakley

series ordinal

2

1 reference

PubMed ID

23964629

29 August 2017

Ralph A Tripp

series ordinal

3

1 reference

29 August 2017

1 August 2013

1 reference

Expert Review of Respiratory Medicine

29 August 2017

1 reference

29 August 2017

7

1 reference

29 August 2017

411-427

1 reference

29 August 2017

4

1 reference

Bronchiolitis-associated hospitalizations among US children, 1980-1996.

29 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

The burden of respiratory syncytial virus infection in young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Mortality associated with influenza and respiratory syncytial virus in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

The burgeoning burden of respiratory syncytial virus among children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Pattern recognition receptors for respiratory syncytial virus infection and design of vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Pattern recognition receptors and genetic risk for rsv infection: value for clinical decision-making?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

The role of Toll-like receptors in regulating the immune response against respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Regulation of immunity to respiratory syncytial virus by dendritic cells, toll-like receptors, and notch

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Pathogenesis of respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

A Toll-like receptor in horseshoe crabs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Respiratory syncytial virus up-regulates TLR4 and sensitizes airway epithelial cells to endotoxin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Role of human TLR4 in respiratory syncytial virus-induced NF-κB activation, viral entry and replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Respiratory syncytial virus-induced activation of nuclear factor-kappaB in the lung involves alveolar macrophages and toll-like receptor 4-dependent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Control of RSV-induced lung injury by alternatively activated macrophages is IL-4R alpha-, TLR4-, and IFN-beta-dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Common human Toll-like receptor 4 polymorphisms--role in susceptibility to respiratory syncytial virus infection and functional immunological relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Increased Toll-like receptor 4 expression in infants with respiratory syncytial virus bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

TLR4 mutations are associated with endotoxin hyporesponsiveness in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Association between common Toll-like receptor 4 mutations and severe respiratory syncytial virus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Innate immunity in respiratory syncytial virus bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Respiratory syncytial virus: immunopathology and control

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Respiratory syncytial virus-induced immunoprotection and immunopathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Innate immune responses in respiratory syncytial virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Binding and entry of respiratory syncytial virus into host cells and initiation of the innate immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Cytokines and respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

The host response and molecular pathogenesis associated with respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Antiviral immune responses and lung inflammation after respiratory syncytial virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Respiratory syncytial virus and other pneumoviruses: a review of the international symposium--RSV 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Biological challenges and technological opportunities for respiratory syncytial virus vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Viral and host factors in human respiratory syncytial virus pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Immunity to and frequency of reinfection with respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Comparison of corticosteroids for treatment of respiratory syncytial virus bronchiolitis and pneumonia in cotton rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Proposed three-dimensional model for the attachment protein G of respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Soluble G protein of respiratory syncytial virus inhibits Toll-like receptor 3/4-mediated IFN-beta induction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Recombinant respiratory syncytial virus lacking secreted glycoprotein G is attenuated, non-pathogenic but induces protective immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Cytotoxic lymphocytes in the lungs of mice infected with respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Analysis of the local and systemic immune responses induced in BALB/c mice by experimental respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

T cell redistribution kinetics after secondary infection of BALB/c mice with respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Developing and maintaining protective CD8+ memory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Clearance of HIV type 1 envelope recombinant sendai virus depends on CD4+ T cells and interferon-gamma but not B cells, CD8+ T cells, or perforin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

CD4(+) T-cell-mediated antiviral protection of the upper respiratory tract in BALB/c mice following parenteral immunization with a recombinant respiratory syncytial virus G protein fragment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Th1 and Th2 subsets: paradigms lost?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Mechanisms of respiratory syncytial virus modulation of airway immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

IL-17-induced pulmonary pathogenesis during respiratory viral infection and exacerbation of allergic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Foxp3+ CD4 regulatory T cells limit pulmonary immunopathology by modulating the CD8 T cell response during respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Role of interferon gamma in the pathogenesis of primary respiratory syncytial virus infection in BALB/c mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Viral load drives disease in humans experimentally infected with respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Respiratory syncytial virus load predicts disease severity in previously healthy infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Respiratory syncytial virus disease: update on treatment and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Therapeutic targeting of respiratory syncytial virus G-protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

A role for immune complexes in enhanced respiratory syncytial virus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

A bovine model of vaccine enhanced respiratory syncytial virus pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Evaluation of BBG2Na in infant macaques: specific immune responses after vaccination and RSV challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Defective immunoregulation in RSV vaccine-augmented viral lung disease restored by selective chemoattraction of regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Age-dependent maturation of Toll-like receptor-mediated cytokine responses in Gambian infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Innate immunity of the newborn: basic mechanisms and clinical correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Phenotype and function of neonatal DC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Influence of maternal antibodies on neonatal immunization against respiratory viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Nonclinical phenotypic and genotypic analyses of a Phase 1 pediatric respiratory syncytial virus vaccine candidate MEDI-559 (rA2cp248/404/1030ΔSH) at permissive and non-permissive temperatures

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Sequential annual administration of purified fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

The respiratory syncytial virus G protein conserved domain induces a persistent and protective antibody response in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

The TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine-enhanced disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

New insights for development of a safe and protective RSV vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

A highly attenuated recombinant human respiratory syncytial virus lacking the G protein induces long-lasting protection in cotton rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

An adjuvanted respiratory syncytial virus fusion protein induces protection in aged BALB/c mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Antibody response to the central unglycosylated region of the respiratory syncytial virus attachment protein in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Humoral response to the central unglycosylated region of the respiratory syncytial virus attachment protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Identification of and human serum reactogenicity to neutralizing epitopes within the central unglycosylated region of the respiratory syncytial virus attachment protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Efficacy and safety studies of a recombinant chimeric respiratory syncytial virus FG glycoprotein vaccine in cotton rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Nucleoprotein nanostructures combined with adjuvants adapted to the neonatal immune context: a candidate mucosal RSV vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Synthetic nanoparticle vaccines produced by layer-by-layer assembly of artificial biofilms induce potent protective T-cell and antibody responses in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Single intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Intranasal vaccination with a helper-dependent adenoviral vector enhances transgene-specific immune responses in BALB/c mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Single mucosal immunization of recombinant adenovirus-based vaccine expressing F1 protein fragment induces protective mucosal immunity against respiratory syncytial virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Absence of vaccine-enhanced RSV disease and changes in pulmonary dendritic cells with adenovirus-based RSV vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Baculovirus-based Vaccine Displaying Respiratory Syncytial Virus Glycoprotein Induces Protective Immunity against RSV Infection without Vaccine-Enhanced Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Long-term and memory immune responses in mice against Newcastle disease virus-like particles containing respiratory syncytial virus glycoprotein ectodomains

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Evaluation of Measles Vaccine Virus as a Vector to Deliver Respiratory Syncytial Virus Fusion Protein or Epstein-Barr Virus Glycoprotein gp350.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Intranasal Sendai virus vaccine protects African green monkeys from infection with human parainfluenza virus-type one.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Human parainfluenza virus type 1 but not Sendai virus replicates in human respiratory cells despite IFN treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Sendai virus-based RSV vaccine protects African green monkeys from RSV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Efficient lung recruitment of respiratory syncytial virus-specific Th1 cells induced by recombinant bacillus Calmette-Guérin promotes virus clearance and protects from infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Partial protection to respiratory syncytial virus (RSV) elicited in mice by intranasal immunization using live staphylococci with surface-displayed RSV-peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Respiratory syncytial virus infection of gene gun vaccinated mice induces Th2-driven pulmonary eosinophilia even in the absence of sensitisation to the fusion (F) or attachment (G) protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Protection against respiratory syncytial virus infection by DNA immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Gene-gun DNA vaccination aggravates respiratory syncytial virus-induced pneumonitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Nonviral delivery of self-amplifying RNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Eosinophils, ribonucleases and host defense: Solving the puzzle

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

Respiratory syncytial virus vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2013.814409

10.1586/17476348.2013.814409

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference

PubMed ID

23964629